TGF-beta 2 Antibody (771244) [Alexa Fluor® 488]

• Reactivity: Mu
• Applications: WB, IHC
• Clone: 771244
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 488

TGF-beta 2 Antibody (771244) [Alexa Fluor® 488] Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant mouse TGF-beta 2
  Ala303-Ser414
  Accession # P27090
• Specificity: Detects mouse TGF‑ beta 2 in ELISAs and Western blots. In direct ELISAs, 100% cross‑reactivity with recombinant human (rh) TGF‑ beta 2, 25% cross‑reactivity with rhTGF‑ beta 3, and no cross‑reactivity with recombinant mouse TGF‑ beta 1 is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TGF-beta 2 Antibody (771244) [Alexa Fluor® 488]

• BSC-1 cell growth inhibitor
• cetermin
• Glioblastoma-derived T-cell suppressor factor
• G-TSF
• MGC116892
• polyergin
• TGFB2
• TGFbeta 2
• TGF-beta 2
• TGF-beta2
• TGF-beta-2
• transforming growth factor beta-2
• transforming growth factor, beta 2

Background

TGF-beta 2 (transforming growth factor beta 2) is one of three closely related mammalian members of the large TGF-beta  superfamily that share a characteristic cysteine knot structure. TGF-beta 1, -2 and -3 are highly pleiotropic cytokines proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition. Each TGF-beta isoform has some non-redundant functions; for TGF-beta 2, mice with targeted deletion show defects in development of cardiac, lung, craniofacial, limb, eye, ear and urogenital systems. Mouse TGF-beta 2 cDNA encodes a 414 amino acid (aa) precursor that contains a 19 aa signal peptide and a 395 aa proprotein. A furin-like convertase processes the proprotein to generate an N-terminal 283 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-  beta 2. Disulfide-linked homodimers of LAP and TGF-beta 2 remain non-covalently associated after secretion, forming the small latent TGF-beta 2 complex. Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix. TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins. Mature mouse TGF-beta 2 shares 100% aa identity with rat TGF-beta 2, and 97% aa identity with human, porcine, canine, equine and bovine TGF-beta 2. It demonstrates cross-species activity. In most cells, TGF-beta 2 signaling begins with binding to a complex of the accessory receptor betaglycan (also known as TGF-beta  RIII) and a type II ser/thr kinase receptor termed TGF-beta  RII, which then phosphorylates and activates another ser/thr kinase receptor, TGF-beta  RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1. The whole complex phosphorylates and activates Smad proteins that regulate transcription. In bone -related cells, however, TGF-beta 2 also signals through TGF-beta RIIB (a splice variant of TGF-beta RII), independently of TGF-beta RIII. Use of other signaling pathways that are Smad-independent allows for disparate actions observed in response to TGF-beta in different contexts.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P27090()